This inventor holds 1 USPTO granted patent and 1 published patent application and 6 EPO patents. Top assignee: Innate Pharma. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020
Title: Nicolaï Wagtmann: Innovator in Cancer Treatment
Introduction
Nicolaï Wagtmann is a prominent inventor based in Cassis, France. He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic regimens. His work focuses on utilizing antibodies to combat diseases, particularly cancer.
Latest Patents
Wagtmann holds a patent for "Treatment regimens using anti-NKG2A antibodies." This invention relates to methods for treating diseases, notably cancer, by using antibodies that specifically bind and inhibit human NKG2A. The patent outlines therapeutic regimens that enhance the efficacy of anti-NKG2A antibodies, providing new avenues for cancer treatment.
Career Highlights
Nicolaï Wagtmann is associated with Innate Pharma, a company dedicated to developing innovative immunotherapies for cancer. His work at Innate Pharma has positioned him as a key player in the advancement of cancer therapies, contributing to the understanding and application of immune-based treatments.
Collaborations
Wagtmann collaborates with notable colleagues, including Pascale Andre and Mathieu Blery. These partnerships enhance the research and development efforts at Innate Pharma, fostering an environment of innovation and discovery.
Conclusion
Nicolaï Wagtmann's contributions to cancer treatment through his patent and work at Innate Pharma highlight his role as an influential inventor in the field. His innovative approaches continue to pave the way for advancements in therapeutic regimens targeting cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile